医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

R-Tech Ueno: Notice of Revisions of Dividend Forecast

2014年02月14日 PM04:10
このエントリーをはてなブックマークに追加


 

TOKYO

R-Tech Ueno, Ltd. (JASDAQ:4573):

A resolution was passed during the Board of Directors’ Meeting held on February 12, 2014 to revise our dividend per share forecast as described below.

1. Reasons for the revisions made to the dividend forecast

We consider the return of profits to shareholders to be one of our important main issues. We will continue to deliver steady dividend distributions to our shareholders while considering future business performance.
In line with this policy and overall consideration of the current business performance and financial conditions, we have increased the expected dividend for the fiscal year ending March 2014 by 5 yen from 20 yen to 25 yen per share.

2. Revisions to the Dividend Forecast

(1) Dividend forecast for the fiscal year ending March 2014

 

  Annual dividend
End of 1st quarter   End of 2nd quarter   End of 3rd quarter   Year-end   Total
Yen Yen Yen Yen Yen
Previous forecast

20.00 20.00
Revised forecast

25.00 25.00
Actual results for the current fiscal year

   

(Reference)
Actual results
(Fiscal year ended March 2013)

 

 

 

  15.00   15.00
 
(Note)   We conducted a 200 for 1 stock split on July 1, 2013. Subsequently, we show the value of dividends for FY3/13 based upon an assumption that the stock split was performed at the start of the previous fiscal year. The dividend payment would be JPY3,000 per share if the effect of the stock split is excluded.
 

About R-Tech Ueno, Ltd.

R-Tech Ueno is a bio venture company established in September 1989 for the purpose of R&D and marketing of drugs. Under the leadership of the CEO, also a medical doctor, the company is developing new drugs on the theme “Physician-Oriented New Drug Innovation”, targeting ophthalmologic and dermatologic diseases that previously had no effective therapeutic agent.

We aim at becoming a “global pharmaceutical company specializing in specific fields (ophthalmology and dermatology) and developing and selling pharmaceutical products through the eyes of doctors.” We are promoting the development of new drugs for unmet medical needs for which the government provides recommendations and assistance, orphan drugs and the drugs in the field of anti-aging (lifestyle drugs).

CONTACT

R-Tech Ueno, Ltd.
Koji Nakamura, +81-3-3596-8011
Director
Business
Management Department
info@rtueno.co.jp

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作
  • ベルタンとザイモリサーチが新しい連携を発表
  • The First China (Chongqing) Selenium Enrichment Industry Development Conference, Organized by the Chongqing Jiangjin Agriculture Commission, Was Held in Jiangjin